Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Marimed (MRMD) EBITDA Margin (2016 - 2025)

Marimed (MRMD) has disclosed EBITDA Margin for 15 consecutive years, with 10.86% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin fell 710.0% to 10.86% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1.65% through Dec 2025, down 346.0% year-over-year, with the annual reading at 1.76% for FY2025, 342.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 10.86% at Marimed, down from 3.92% in the prior quarter.
  • The five-year high for EBITDA Margin was 36.85% in Q2 2021, with the low at 10.86% in Q4 2025.
  • Average EBITDA Margin over 5 years is 9.56%, with a median of 7.34% recorded in 2023.
  • Peak annual rise in EBITDA Margin hit 1507bps in 2021, while the deepest fall reached -3561bps in 2021.
  • Over 5 years, EBITDA Margin stood at 3.88% in 2021, then skyrocketed by 122bps to 8.62% in 2022, then fell by -28bps to 6.2% in 2023, then plummeted by -161bps to 3.77% in 2024, then crashed by -188bps to 10.86% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 10.86%, 3.92%, and 2.88% for Q4 2025, Q3 2025, and Q2 2025 respectively.